Texto completo (219)
- Antivirales (205)
- Gripe Humana (152)
- Subtipo H1N1 del Virus de la Influenza A (145)
- Virus de la Influenza A (42)
- Farmacorresistencia Viral (37)
- Oseltamivir (33)
- Infecciones por Orthomyxoviridae (28)
- Brotes de Enfermedades (24)
- Subtipo H3N2 del Virus de la Influenza A (21)
- Pandemias (20)
- Virus de la Influenza B (15)
- Subtipo H5N1 del Virus de la Influenza A (13)
- Zanamivir (13)
- Neuraminidasa (12)
- Orthomyxoviridae (10)
- Vacunas contra la Influenza (10)
- Gripe Aviar (9)
- Proteínas Virales (8)
- Pautas en la Práctica de los Médicos (7)
- Extractos Vegetales (7)
- Mostrar más...
- Antiviral Res (21)
- PLoS One (15)
- Influenza Other Respir Viruses (11)
- Clin Infect Dis (9)
- J Virol (9)
- J Infect Dis (7)
- Vopr Virusol (7)
- Antimicrob Agents Chemother (6)
- J Immunol (5)
- Antibiot Khimioter (4)
- J Antimicrob Chemother (4)
- J Clin Virol (4)
- J Virol Methods (4)
- J Gen Virol (3)
- J Med Virol (3)
- J Microbiol (3)
- PLoS Curr (3)
- Virus Res (3)
- Acta Biochim Pol (2)
- Am J Physiol Lung Cell Mol Physiol (2)
- Mostrar más...
Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses.
Fuente: Antiviral Res;120: 101-11, 2015 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26022197
Resumen: The influenza A virus is notoriously known for its ability to cause recurrent epidemics and global pandemics. Antiviral therapy is effective when treatment is initiated within 48h of symptom onset, and delaying treatment beyond this time frame is associated with decreased efficacy. Research on anti-inflammatory therapy to ameliorate influenza-induced inflammation is currently underway and seems important to the impact on the clinical outcome. Both antiviral and anti-inflammatory drugs with (mas)
Influenza A Virus Protein PA-X Contributes to Viral Growth and Suppression of the Host Antiviral and Immune Responses.
Fuente: J Virol;89(12): 6442-52, 2015 Jun.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25855745
Resumen: UNLABELLED: Influenza virus infection causes global inhibition of host protein synthesis in infected cells. This host shutoff is thought to allow viruses to escape from the host antiviral response, which restricts virus replication and spread. Although the mechanism of host shutoff is unclear, a novel viral protein expressed by ribosomal frameshifting, PA-X, was found to play a major role in influenza virus-induced host shutoff. However, little is known about the impact of PA-X expression o (mas)
Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain.
Fuente: Med Intensiva;39(4): 222-33, 2015 May.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25107582
Resumen: OBJECTIVE: To determine the degree of antiviral treatment recommendations adherence and its impact to critical ill patients affected by influenza A(H1N1)pdm09 mortality. DESIGN: Secondary analysis of prospective study. SETTING: Intensive care (UCI). PATIENTS: Patients with influenza A(H1N1)pdm09 in the 2009 pandemic and 2010-11 post-Pandemic periods. VARIABLES: Adherence to recommendations was classified as: Total (AT); partial in doses (PD); partial in time (PT), and non-adherence (NA). Vi (mas)
Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses.
Fuente: PLoS One;10(4): e0124706, 2015.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25909853
Resumen: Human LL-37, a cationic antimicrobial peptide, was recently shown to have antiviral activity against influenza A virus (IAV) strains in vitro and in vivo. In this study we compared the anti-influenza activity of LL-37 with that of several fragments derived from LL-37. We first tested the peptides against a seasonal H3N2 strain and the mouse adapted H1N1 strain, PR-8. The N-terminal fragment, LL-23, had slight neutralizing activity against these strains. In LL-23V9 serine 9 is substituted by (mas)
Mitochondrial antiviral signaling adaptor mediated apoptosis in H3N2 swine influenza virus infection is inhibited by viral protein NS1 in vitro.
Fuente: Vet Immunol Immunopathol;165(1-2): 34-44, 2015 May 15.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25800220
Resumen: We investigated the in vitro role of mitochondrial antiviral signaling adaptor (MAVS) in apoptosis induced by H3N2 swine influenza virus infection and the influence of viral NS1 (nonstructural protein 1) protein on this process. H3N2 swine influenza virus (SIV, A/Swine/Shandong/3/2005) was co-cultured with human lung epithelial A549 cells. The relationship of MAVS expression to SIV replication and apoptosis, and the influence of viral proteins on MAVS functions were studied. The data indica (mas)
Fuente: Epidemiol Infect;143(8): 1621-31, 2015 Jun.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25274250
Resumen: Vaccines are the cornerstone of influenza control policy, but can suffer from several drawbacks. Seasonal influenza vaccines are prone to production problems and low efficacies, while pandemic vaccines are unlikely to be available in time to slow a rapidly spreading global outbreak. Antiviral therapy was found to be beneficial during the influenza A(H1N1)pdm09 pandemic even with limited use; however, antiviral use has decreased further since then. We sought to determine the role antiviral t (mas)
Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic.
Fuente: Clin Infect Dis;60 Suppl 1: S30-41, 2015 May 1.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25878299
Resumen: Following the detection of a novel influenza strain A(H7N9), we modeled the use of antiviral treatment in the United States to mitigate severe disease across a range of hypothetical pandemic scenarios. Our outcomes were total demand for antiviral (neuraminidase inhibitor) treatment and the number of hospitalizations and deaths averted. The model included estimates of attack rate, healthcare-seeking behavior, prescription rates, adherence, disease severity, and the potential effect of antivi (mas)
Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.
Fuente: Mol Pharm;12(3): 910-21, 2015 Mar 2.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25599953
Resumen: Pulmonary delivery of siRNA has considerable therapeutic potential for treating viral respiratory infectious diseases including influenza. By introducing siRNA that targets the conserved region of viral genes encoding nucleocapsid protein (NP), viral mRNAs can be degraded and viral replication can be inhibited in mammalian cells. To enable siRNA to be used as an antiviral agent, the nucleic acid delivery barrier must be overcome. Effective local delivery of siRNA to lung tissues is required (mas)
A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.
Fuente: PLoS One;10(3): e0118780, 2015.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25738900
Resumen: Ferrets are the preferred animal model to assess influenza virus infection, virulence and transmission as they display similar clinical symptoms and pathogenesis to those of humans. Measures of disease severity in the ferret include weight loss, temperature rise, sneezing, viral shedding and reduced activity. To date, the only available method for activity measurement has been the assignment of an arbitrary score by a 'blind' observer based on pre-defined responsiveness scale. This manual s (mas)
Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance.
Fuente: Mem Inst Oswaldo Cruz;110(1): 101-5, 2015 Feb.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25742269
Resumen: The 2009 pandemic influenza A virus outbreak led to the systematic use of the neuraminidase (NA) inhibitor oseltamivir (OST). Consequently, OST-resistant strains, carrying the mutation H275Y, emerged in the years after the pandemics, with a prevalence of 1-2%. Currently, OST-resistant strains have been found in community settings, in untreated individuals. To spread in community settings, H275Y mutants must contain additional mutations, collectively called permissive mutations. We display t (mas)
In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase.
Fuente: Chem Biol Drug Des;85(4): 427-38, 2015 Apr.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25185493
Resumen: The anti-influenza virus activities of 50 resveratrol (RV: 3, 5, 4'-trihydroxy-trans-stilbene) derivatives were evaluated using a neuraminidase (NA) activity assay. The results showed that 35 compounds exerted an inhibitory effect on the NA activity of the influenza virus strain A/PR/8/34 (H1N1) with 50% inhibitory concentration (IC50) values ranging from 3.56 to 186.1 µm. Next, the 35 RV derivatives were used to develop 3D quantitative structure-activity relationship (3D QSAR) models for (mas)
Fuente: Eur J Immunol;45(3): 758-72, 2015 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25404059
Resumen: The NLR protein, NLRC5 is an important regulator of MHC class I gene expression, however, the role of NLRC5 in other innate immune responses is less well defined. In the present study, we report that NLRC5 binds RIG-I and that this interaction is critical for robust antiviral responses against influenza virus. Overexpression of NLRC5 in the human lung epithelial cell line, A549, and normal human bronchial epithelial cells resulted in impaired replication of influenza virus A/Puerto Rico/8/3 (mas)